BidaskClub Upgrades Heska (HSKA) to Sell
Several other brokerages have also recently commented on HSKA. ValuEngine cut shares of Heska from a buy rating to a hold rating in a report on Wednesday, May 1st. Zacks Investment Research downgraded shares of Heska from a buy rating to a strong sell rating in a research note on Tuesday, March 5th. B. Riley lowered their target price on shares of Heska from $93.00 to $87.00 and set a neutral rating for the company in a research note on Wednesday, February 27th. Benchmark downgraded shares of Heska from a buy rating to a hold rating in a research note on Wednesday, February 27th. Finally, Sidoti downgraded shares of Heska from a buy rating to a neutral rating in a research note on Tuesday, February 26th. Two investment analysts have rated the stock with a sell rating, four have issued a hold rating and one has assigned a buy rating to the company. The stock presently has an average rating of Hold and an average price target of $109.00.
Shares of NASDAQ HSKA opened at $81.87 on Tuesday. The firm has a market capitalization of $613.80 million, a P/E ratio of 57.65 and a beta of 0.73. Heska has a 1-year low of $71.50 and a 1-year high of $114.50.
In other Heska news, COO Jason A. Napolitano sold 7,500 shares of Heska stock in a transaction on Thursday, February 14th. The shares were sold at an average price of $97.73, for a total value of $732,975.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 14.00% of the stock is owned by company insiders.
Institutional investors and hedge funds have recently bought and sold shares of the business. Texas Permanent School Fund increased its position in shares of Heska by 3.8% during the first quarter. Texas Permanent School Fund now owns 4,638 shares of the medical research company’s stock worth $395,000 after acquiring an additional 168 shares in the last quarter. Rhumbline Advisers increased its holdings in Heska by 1.0% during the 1st quarter. Rhumbline Advisers now owns 19,630 shares of the medical research company’s stock worth $1,671,000 after acquiring an additional 191 shares during the period. SG Americas Securities LLC bought a new position in shares of Heska in the 1st quarter worth $195,000. BNP Paribas Arbitrage SA boosted its stake in shares of Heska by 47,400.0% in the 1st quarter. BNP Paribas Arbitrage SA now owns 1,425 shares of the medical research company’s stock valued at $121,000 after purchasing an additional 1,422 shares in the last quarter. Finally, Conestoga Capital Advisors LLC purchased a new stake in shares of Heska in the 1st quarter valued at $229,000. 83.03% of the stock is owned by hedge funds and other institutional investors.
Heska Corporation manufactures, sells, and markets veterinary diagnostic and specialty products for canine and feline healthcare markets in the United States, Canada, Europe, and internationally. The company's Core Companion Animal segment offers Element DC and DRI-CHEM 7000 veterinary chemistry analyzers for blood chemistry and electrolyte analysis; Element HT5 and HemaTrue veterinary hematology analyzers to measure blood cell and platelet count, and hemoglobin levels; Element POC blood gas and electrolyte analyzers; Element i immunodiagnostic analyzers; Element COAG veterinary analyzers; and IV infusion pumps.
Recommended Story: What is a Fibonacci Channel?
Receive News & Ratings for Heska Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heska and related companies with MarketBeat.com's FREE daily email newsletter.